CompletedPhase 2

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

United States75 participantsStarted 2004-04

Plain-language summary

This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically confirmed primary endometrioid adenocarcinoma of the uterine corpus * All histologic grades and stages eligible * Diagnosis by endometrial curettage or biopsy within the past 8 weeks * Must have the initial tissue block or 16 unstained sections of 5 micron thickness available * Performance status - GOG 0-3 * No history of thrombophlebitis or thromboembolic disorders * No other invasive malignancy within the past 5 years except nonmelanoma skin cancer * No prior therapeutic progesterone or anti-estrogen therapy within 3 months before diagnosis * No concurrent aminoglutethimide * No prior cancer treatment that would preclude study therapy * No concurrent bosentan * No concurrent rifampin

What they're measuring

Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor Negative

Timeframe: During the hysterectomy, which is 21-24 days after administration of depo-provera

Trial details

NCT IDNCT00064025

SponsorGynecologic Oncology Group

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2010-09

Results submitted2014-01-31

View on ClinicalTrials.gov More Endometrial Adenocarcinoma trials